A Phase 1/2 interventional study of GZR18 and Placebo in Obesity and Overweight, sponsored by Gan and Lee Pharmaceuticals, USA. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bofanglutide in Obesity — 3 open to participants now, 3 under way, 3 of them phase 3. bofanglutide · Obesity.
Among the 15 studies testing bofanglutide in Obesity, this one is the 9th largest by enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 1st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →3 of the 15 studies testing bofanglutide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Gan & Lee Pharmaceuticals. · Sites in China
Ages 18+
Carnot Laboratories · Sites in Mexico
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 5
First in 2021; this study’s year is marked. 1 started in 2022.
This study's enrollment of 60 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 140 across the 15 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 3 most frequent:
This study is registered under Gan and Lee Pharmaceuticals, USA, one of the names counted as Gan & Lee Pharmaceuticals. Under that name alone:
Gan and Lee Pharmaceuticals, USA is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
15 studies in Obesity by Gan & Lee Pharmaceuticals: 3 open now, 3 under way, 2 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 15 studies in Obesity by Gan & Lee Pharmaceuticals, this one is the 9th largest by enrollment, is the only one that started in 2022, is the only one in phase 1/2, and was the 1st registered.
Gan & Lee Pharmaceuticals’s Obesity studies by the year they started, since 2021.
2 of the studies testing bofanglutide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07150975Phase 3Gan & Lee Pharmaceuticals.Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects | 2027-06-30 |
| NCT07493057Phase 3Gan & Lee Pharmaceuticals.Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy | 2027-11-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing bofanglutide in Obesity, from their registry updates:
Among Gan & Lee Pharmaceuticals’s 15 in Obesity:
This tab as a report to print or save as PDF → With an account.
The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight patients. This study is divided into Part A and Part B, which are to be conducted simultaneously.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female aged 18-65 years (inclusive);
Exclusion Criteria:
Suspicion that the subject may be allergic to any study drug or ingredient or congener from the investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GZR18 injection s.c.
Drug: GZR18
Placebo injection s.c.
Other: Placebo
0.6 mg-30 mg
administered the same volume as GZR18
Incidence of adverse events and serious adverse events
Time frame: 38 weeks
Changes in weight from baseline to the end of treatment
Time frame: 35 weeks
trough concentrations following consecutive doses
Time frame: 35 weeks
Changes in Body mass index (BMI) from baseline to the end of treatment
Time frame: 35 weeks
Changes in Percentage of reduction in weight (%) from baseline to the end of treatment
Time frame: 35 weeks
Changes in Waist circumference from baseline to the end of treatment
Time frame: 35 weeks
Proportion of subjects with ≥5% reduction in body weight from baseline.
Time frame: 35 weeks
Ran from Jul 2022 to primary completion in Oct 2023, 15 months.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bofanglutide
Gan and Lee Pharmaceuticals, USA →